SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (307)1/13/2008 5:24:56 PM
From: Gary Mohilner  Read Replies (1) of 684
 
As I understand this trial it's for patients who don't have Mets, but for whom the SOC is 11 months, not 5 years. I don't know if the drug will have much benefits for patients with Mets, but even if not, it may extend or save the life of many who don't.

If in fact the drug does give 19 months on average to patients that the SOC only gives 11, I believe it should be approved for that application on the next peek at the data. Cures are a rarity with Pancreatic Cancer, but if the cancer's being killed by the drug I don't know that it can't work its way through the Mets, but that would be the subject of a completely different trial. For now approval would only be for patients without Mets.

Of course everyone knows it will be tried off label for other applications, it's actually getting some good results in Phase II in other cancers, so expansion of the applications should almost certainly come, whether it includes Pancreatic cancer with mets or not.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News